Novo Nordisk’s adjusted operating profit reached DKK 32,858 million in Q1 2026
Bagsværd, Denmark, 6 May 2026 - Financial report for the period 1…
Novo Nordisk files annual report with the SEC
Bagsværd, Denmark, 4 February 2026 – Novo Nordisk A/S has filed its…
New employee representative on the Board of Directors of Novo Nordisk A/S
Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board…
Novo Nordisks Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater…
Novo Nordisk A/S: Wegovy approved in the US for the treatment of MASH
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US…
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig)…
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed…
